Protocol Ledger

NCT04663308 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Interventional Phase II clinical trial protocol NCT04663308 sponsored by Mirum Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-18 Enrollment: 182 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04663308
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)182 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04663308
Protocol FieldVerified Registry Value
NCT IdentifierNCT04663308
Consolidated Lead SponsorMirum Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment182 participants (ACTUAL)
Registered Start Date2020-12-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI